Abuelezz and colleagues investigated the impact of PCSK9-inhibitor alirocumab in brain cholesterol metabolism, dyslipidemia, and neuroinflammation, which are markers of AD risk and pathology [99]. The gene discussed is PCSK9; the disease is Alzheimer disease.